A look at Ionis Pharmaceuticals Inc’s (IONS) recent performance gives investors their first glimpse of hope.

On Monday, Ionis Pharmaceuticals Inc (NASDAQ: IONS) opened higher 4.07% from the last session, before settling in for the closing price of $36.61. Price fluctuations for IONS have ranged from $33.33 to $54.44 over the past 52 weeks.

Healthcare Sector giant saw their annual sales surged by 13.97% over the last five years. Company’s average yearly earnings per share was noted -33.96% at the time writing. With a float of $145.55 million, this company’s outstanding shares have now reached $157.81 million.

The firm has a total of 927 workers. Let’s measure their productivity. In terms of profitability, gross margin is 97.3%, operating margin of -46.11%, and the pretax margin is -44.29%.

Ionis Pharmaceuticals Inc (IONS) Insider Activity

A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Ionis Pharmaceuticals Inc is 7.82%, while institutional ownership is 98.05%. The most recent insider transaction that took place on Nov 12 ’24, was worth 45,278. In this transaction EVP Research of this company sold 1,194 shares at a rate of $37.92, taking the stock ownership to the 33,713 shares. Before that another transaction happened on Nov 12 ’24, when Company’s Chief Executive Officer sold 6,630 for $38.05, making the entire transaction worth $252,294. This insider now owns 167,393 shares in total.

Ionis Pharmaceuticals Inc (IONS) Earnings and Forecasts

Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.99 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around -33.96% per share during the next fiscal year.

Ionis Pharmaceuticals Inc (NASDAQ: IONS) Trading Performance Indicators

Check out the current performance indicators for Ionis Pharmaceuticals Inc (IONS). In the past quarter, the stock posted a quick ratio of 8.82. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.41.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.44, a number that is poised to hit -1.09 in the next quarter and is forecasted to reach -3.42 in one year’s time.

Technical Analysis of Ionis Pharmaceuticals Inc (IONS)

Analysing the last 5-days average volume posted by the [Ionis Pharmaceuticals Inc, IONS], we can find that recorded value of 1.54 million was better than the volume posted last year of 1.34 million. As of the previous 9 days, the stock’s Stochastic %D was 40.93%. Additionally, its Average True Range was 1.46.

During the past 100 days, Ionis Pharmaceuticals Inc’s (IONS) raw stochastic average was set at 25.09%, which indicates a significant decrease from 60.78% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 31.30% in the past 14 days, which was lower than the 40.08% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $37.56, while its 200-day Moving Average is $42.09. Now, the first resistance to watch is $39.20. This is followed by the second major resistance level at $40.31. The third major resistance level sits at $41.71. If the price goes on to break the first support level at $36.69, it is likely to go to the next support level at $35.29. Should the price break the second support level, the third support level stands at $34.18.

Ionis Pharmaceuticals Inc (NASDAQ: IONS) Key Stats

There are currently 157,897K shares outstanding in the company with a market cap of 5.95 billion. Presently, the company’s annual sales total 787,650 K according to its annual income of -366,290 K. Last quarter, the company’s sales amounted to 133,810 K and its income totaled -140,480 K.